factual

Personalized Cancer Vaccine Cut Recurrence by Half

In a randomized phase two study of patients with early-stage skin cancer, a personalized mRNA vaccine given after surgery cut the recurrence rate of cancer by about 50 percent relative to standard of care.

factualpending

Speaker

Tal Zaks

Evidence Quote

“when you give a personalized vaccine to those patients, it cuts the recurrence rate of cancer by about half, by about 50%, which is quite significant.”

Source

Bridging Science, Medicine, and Returns— Invest Like the Best
Created: 11/19/2026, 4:01:33 PM

Your notes

Loading notes...